Lv1
10 积分 2025-10-21 加入
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
1天前
求助中
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1天前
已完结
Chronic urticaria in Chinese population: a hospital-based multicenter epidemiological study
24天前
已完结
Prevalence and risk factors of chronic urticaria in China: A nationwide cross‐sectional study
24天前
已完结
Worldwide prevalence of prurigo nodularis: A systematic review and meta‐analysis
24天前
已完结
Chronic Spontaneous Urticaria
25天前
已完结
Chronic Spontaneous Urticaria
25天前
已完结
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
26天前
已完结
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
29天前
已完结
Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps
29天前
已完结
皖公网安备34019202002308
